Clover Biopharmaceuticals (HKSE:02197) Equity-to-Asset : -0.35 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Clover Biopharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Clover Biopharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$-801.56 Mil. Clover Biopharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was HK$2,298.50 Mil. Therefore, Clover Biopharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -0.35.

The historical rank and industry rank for Clover Biopharmaceuticals's Equity-to-Asset or its related term are showing as below:

HKSE:02197' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.83 Med: -0.35 Max: 0.23
Current: -0.35

During the past 5 years, the highest Equity to Asset Ratio of Clover Biopharmaceuticals was 0.23. The lowest was -0.83. And the median was -0.35.

HKSE:02197's Equity-to-Asset is ranked worse than
88.19% of 1558 companies
in the Biotechnology industry
Industry Median: 0.67 vs HKSE:02197: -0.35

Clover Biopharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Clover Biopharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clover Biopharmaceuticals Equity-to-Asset Chart

Clover Biopharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

-0.36

-0.83

0.23

-0.14

-0.35

Clover Biopharmaceuticals Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial			0.23	0.03	-0.14	0.01	-0.35

Competitive Comparison of Clover Biopharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, Clover Biopharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clover Biopharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clover Biopharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Clover Biopharmaceuticals's Equity-to-Asset falls into.

Clover Biopharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Clover Biopharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-801.557	/	2298.504
	=	-0.35

Clover Biopharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-801.557	/	2298.504
	=	-0.35

Clover Biopharmaceuticals (HKSE:02197) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Clover Biopharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Clover Biopharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Clover Biopharmaceuticals (HKSE:02197) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clover Biopharmaceuticals Ltd (HKSE:02197) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1598-1601 West Nanjing Road, 49th Floor, Park Place, Jing’an District, Shanghai, CHN

Website

https://www.cloverbiopharma.com

Clover Biopharmaceuticals Ltd is a clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates for infectious diseases as well as cancer and autoimmune diseases.

Executives

Liang Peng	2101 Beneficial owner
Liang Joshua G	2501 Other
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager
Aut-xxi Investment Holdings Limited	2201 Interest of corporation controlled by you
Jnry V Holdings Limited	2101 Beneficial owner
Aut-xxi Hk Holdings Limited	2101 Beneficial owner
Aut-xxi Holdings Limited	2201 Interest of corporation controlled by you
Hh Imv Holdings, L.p.	2201 Interest of corporation controlled by you
Hillhouse Fund Iv, L.p.	2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
The Core Trust Company Limited	2301 Trustee
Tct (bvi) Limited	2501 Other
Super Novel International Limited	2306 Nominee for another person
Shang Hai Tian He Sheng Tai Qi Ye Guan Li He Huo Qi Ye You Xian He Huo

Clover Biopharmaceuticals (HKSE:02197) Headlines

No Headlines